Rapid CommunicationShort Communication
Implications for Metabolite Quantification by Mass Spectrometry in the Absence of Authentic Standards
Panos Hatsis, Nigel J. Waters and Upendra A. Argikar
Drug Metabolism and Disposition May 2017, 45 (5) 492-496; DOI: https://doi.org/10.1124/dmd.117.075259
Panos Hatsis
Drug Metabolism & Pharmacokinetics, Novartis Institutes for Biomedical Research Inc., East Hanover, New Jersey (P.H); Syros Pharmaceuticals, Cambridge, Massachusetts (N.J.W); and Analytical Sciences & Imaging, Novartis Institutes for Biomedical Research Inc., Cambridge, Massachusetts (U.A.A)
Nigel J. Waters
Drug Metabolism & Pharmacokinetics, Novartis Institutes for Biomedical Research Inc., East Hanover, New Jersey (P.H); Syros Pharmaceuticals, Cambridge, Massachusetts (N.J.W); and Analytical Sciences & Imaging, Novartis Institutes for Biomedical Research Inc., Cambridge, Massachusetts (U.A.A)
Upendra A. Argikar
Drug Metabolism & Pharmacokinetics, Novartis Institutes for Biomedical Research Inc., East Hanover, New Jersey (P.H); Syros Pharmaceuticals, Cambridge, Massachusetts (N.J.W); and Analytical Sciences & Imaging, Novartis Institutes for Biomedical Research Inc., Cambridge, Massachusetts (U.A.A)
Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Rapid CommunicationShort Communication
Mass Spectrometric Responses of Drugs and Metabolites
Panos Hatsis, Nigel J. Waters and Upendra A. Argikar
Drug Metabolism and Disposition May 1, 2017, 45 (5) 492-496; DOI: https://doi.org/10.1124/dmd.117.075259
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement